Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 Jun;9(3):824-827.
doi: 10.21037/tlcr.2020.04.12.

Pembrolizumab-the "KEY" to an evolving landscape in treatment of squamous non-small cell lung cancer (NSCLC)

Amulya Yellala  1 , Apar Kishor Ganti  2
Affiliations
Editorial

Pembrolizumab-the "KEY" to an evolving landscape in treatment of squamous non-small cell lung cancer (NSCLC)

Amulya Yellala et al. Transl Lung Cancer Res. 2020 Jun.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/tlcr.2020.04.12). AKG reports grants and personal fees from AstraZeneca, non-financial support from Takeda, personal fees and other from Roche, grants from Merck, grants and other from Apexigen, grants and other from Novartis, outside the submitted work. AY has no conflicts of interest to declare.

Comment on

  • Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer.
    Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gümüş M, Mazières J, Hermes B, Çay Şenler F, Csőszi T, Fülöp A, Rodríguez-Cid J, Wilson J, Sugawara S, Kato T, Lee KH, Cheng Y, Novello S, Halmos B, Li X, Lubiniecki GM, Piperdi B, Kowalski DM; KEYNOTE-407 Investigators. Paz-Ares L, et al. N Engl J Med. 2018 Nov 22;379(21):2040-2051. doi: 10.1056/NEJMoa1810865. Epub 2018 Sep 25. N Engl J Med. 2018. PMID: 30280635 Clinical Trial.

References

    1. Lortet-Tieulent J, Soerjomataram I, Ferlay J, et al. International trends in lung cancer incidence by histological subtype: adenocarcinoma stabilizing in men but still increasing in women. Lung Cancer 2014;84:13-22. 10.1016/j.lungcan.2014.01.009 - DOI - PubMed
    1. Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med 2016;375:1823-33. 10.1056/NEJMoa1606774 - DOI - PubMed
    1. Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. N Engl J Med 2018;379:2040-51. 10.1056/NEJMoa1810865 - DOI - PubMed
    1. Leclerc M, Mezquita L, Guillebot De Nerville G, et al. Recent Advances in Lung Cancer Immunotherapy: Input of T-Cell Epitopes Associated With Impaired Peptide Processing. Front Immunol 2019;10:1505. 10.3389/fimmu.2019.01505 - DOI - PMC - PubMed
    1. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med 2015;373:123-35. 10.1056/NEJMoa1504627 - DOI - PMC - PubMed